Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Price Target at $40.78

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned a consensus recommendation of “Buy” from the nine brokerages that are covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $43.11.

Several equities analysts have recently weighed in on DYN shares. HC Wainwright raised their target price on Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, May 20th. Jefferies Financial Group raised their price objective on Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, May 20th. JPMorgan Chase & Co. upped their target price on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. Chardan Capital raised their price target on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, May 21st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research note on Monday, May 6th.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $41.54 on Monday. The firm has a fifty day moving average of $32.30 and a 200 day moving average of $26.40. The firm has a market cap of $3.63 billion, a PE ratio of -10.46 and a beta of 1.07. Dyne Therapeutics has a one year low of $6.40 and a one year high of $42.56.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, hitting analysts’ consensus estimates of ($0.81). On average, equities analysts predict that Dyne Therapeutics will post -3 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 2,588 shares of Dyne Therapeutics stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total value of $73,162.76. Following the sale, the senior vice president now owns 116,695 shares in the company, valued at $3,298,967.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Susanna Gatti High sold 10,163 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Richard William Scalzo sold 2,588 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $73,162.76. Following the sale, the senior vice president now directly owns 116,695 shares in the company, valued at approximately $3,298,967.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 202,133 shares of company stock worth $6,500,387. Insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors have recently modified their holdings of DYN. Wetzel Investment Advisors Inc. acquired a new position in Dyne Therapeutics during the 1st quarter worth approximately $28,000. Ameritas Investment Partners Inc. increased its holdings in shares of Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after acquiring an additional 1,291 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Dyne Therapeutics during the 2nd quarter worth about $217,000. China Universal Asset Management Co. Ltd. lifted its stake in Dyne Therapeutics by 355.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock worth $94,000 after purchasing an additional 5,541 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new position in Dyne Therapeutics in the first quarter valued at approximately $214,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.